Skip to main content
RMD Open logoLink to RMD Open
. 2023 Dec 19;9(4):e003317corr1. doi: 10.1136/rmdopen-2023-003317corr1

Correction: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

PMCID: PMC10748967  PMID: 38114200

Kivitz A, Wang L, Alevizos I, et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open 2023;9:e003317. doi: 10.1136/rmdopen-2023-003317

In this article, Figure 4 has been updated to resolve an error.


Articles from RMD Open are provided here courtesy of BMJ Publishing Group

RESOURCES